• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > AstraZeneca > February 08, 2011

      AstraZeneca, Taj Pharma launch Gemcitabine HCI for Injection in US

      Posted Atdrugdiscovery.pharmaceutical-business-review.com

      AstraZeneca Pharmaceuticals and Taj Pharmaceuticals, an India-based manufacturer of generic drugs as well as specialty pharmaceuticals and active pharmaceutical ingredients, have commercially launched Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials in the US.

      Gemcitabine HCI for Injection, the generic version of Gemcitabine HCI, was launched pursuant to a commercialization, manufacture and supply agreement signed by AstraZeneca and Taj Pharmaceuticals, indiacompanynews.com reported.

      As per the agreement, AstraZeneca will manufacture Gemcitabine HCI for Injection and will receive a license to market the product within the India-based firm's 180-day exclusivity.

      Taj Pharma will get a royalty during the manufacturing period.

      Indiacompanynews.com has quoted Taj Pharmaceuticals Generics senior vice president Ajay Sodhi sa saying that the agreement allows them to accelerate the availability of the important generic product Gemcitabine HCI.

      Feb 08, 2011


       

      Share this Article!

    Back to top^